ZOLGENSMA

Indicated For

Spinal muscular atrophy (SMA)

About This Medication

# Novartis Patient Assistance Program for ZOLGENSMA Patient Guide: How to Get ZOLGENSMA (onasemnogene abeparvovec-xioi) at Low or No Cost ZOLGENSMA (onasemnogene abeparvovec-xioi) is a one-time gene therapy treatment for spinal muscular atrophy (SMA) in children under 2 years old, and the Novartis Patient Assistance Program helps eligible families access it at low or no cost through financial and insurance support.[1][2] ## About ZOLGENSMA **ZOLGENSMA** is a groundbreaking gene therapy designed to treat **spinal muscular atrophy (SMA)**, a rare genetic disease that causes muscle weakness and can be life-threatening if untreated. Unlike daily medications, ZOLGENSMA is administered just **once** via intravenous infusion, delivering a functional copy of the SMN1 gene to motor neuron cells to help produce the survival motor neuron (SMN) protein essential for muscle function.[1][2] It's FDA-approved for children less than 2 years old with confirmed SMA diagnosis, including genetic confirmation of SMN1 mutation and specific clinical criteria.[9] This therapy offers hope for slowing or halting SMA progression, potentially improving motor milestones like sitting, standing, or walking. However, its high cost—often over $2 million—makes patient assistance programs crucial. Novartis Patient Support provides dedicated help from enrollment to post-treatment, including a personal **Case Coordinator** who guides families through insurance navigation, financial aid, and treatment tracking.[1][2][4] ## Who Qualifies for the Program? The Novartis Patient Assistance Program for ZOLGENSMA serves **US residents** (including territories) who meet specific criteria based on insurance and financial need. It's divided into two main tracks: - **Commercially Insured Patients**: Eligible for the **ZOLGENSMA CopayAssist™ Program**, which covers copays, deductibles, and coinsurance up to a maximum benefit (call to verify exact amount, often substantial support).[1][2][6] - **Uninsured or Underinsured Patients**: Qualify for the **Novartis Patient Assistance Program** (via Novartis Patient Assistance Foundation, NPAF) if they have limited/no prescription coverage, meet income guidelines, have a valid prescription, and are treated outpatient by a US-licensed provider.[3][5] All patients must reside in the US or a US territory and have a prescription for ZOLGENSMA from a qualified healthcare provider.[3][5] Novartis Patient Support is not a clinical service but complements your doctor's care.[1][2] ## Income Eligibility Breakdown Specific income thresholds for ZOLGENSMA are not publicly listed in fixed amounts and vary; families must check eligibility via www.PAP.Novartis.com or by calling (855) 441-4363. Generally, NPAF targets low-income households (often up to 400-500% of the Federal Poverty Level, depending on household size and medication).[3][5] Here's a general example table based on typical Novartis PAP guidelines (confirm current details with program): | Household Size | Annual Income Limit (Example: 400% FPL) | |----------------|-----------------------------------------| | 1 | $58,320 | | 2 | $78,880 | | 3 | $99,440 | | 4 | $120,000 | | +1 person | +$20,560 | *Note: Exact thresholds require program verification as they adjust annually. No income limits apply to CopayAssist for commercially insured.*[3][5] ## Insurance Requirements - **Commercially Insured**: Eligible for CopayAssist to reduce out-of-pocket costs on ZOLGENSMA.[1][2][6] - **Uninsured/Underinsured**: Eligible for free medication through Patient Assistance if income-qualified.[3][5] - **Medicare/Medicaid**: Generally not eligible for PAP (government insurance excludes most manufacturer free-drug programs); explore state programs or appeals.[3] Your Case Coordinator verifies benefits, assists with prior authorizations (PA), and handles appeals.[1][2][9] ## Step-by-Step Application Process 1. **Get Prescribed**: Confirm SMA diagnosis and eligibility (e.g., age <2, negative AAV9 antibodies). Your doctor prescribes ZOLGENSMA.[9] 2. **Contact Novartis**: Call **(855) 441-4363** (Mon-Fri, 8 AM-8 PM ET) or visit **www.zolgensma-enrollment.com**.[1][2][4] 3. **Complete Required Forms**: - **Novartis Patient Support Start Form** (required for all; includes consents for support services).[4][7] - **ZOLGENSMA Prescription Form**.[1] Fax to 1-855-951-4363 or upload online.[4] 4. **Submit Documents**: Doctor completes their section; provide proof of income/residency if applying for PAP.[3][5] 5. **Meet Case Coordinator**: Upon enrollment, get assigned a dedicated coordinator for insurance/financial guidance.[1][2] 6. **Track Progress**: Coordinator handles benefits verification, PA/appeals, and coordinates delivery.[1][2] Application methods include phone, online upload, or fax.[4] ## Timeline and Delivery - **Processing**: PAP decisions within ~4 weeks; CopayAssist faster upon verification.[3][9] - **Overall Timeline**: Enrollment immediate; PA 14-30 days (expedited 72 hours if urgent).[9] From approval to infusion: 1-2 weeks.[9] - **Delivery**: Coordinated to certified infusion center; tracked by Case Coordinator.[1][2] Exact times vary; your coordinator provides updates. ## Alternatives if Denied - **Appeal**: Coordinator helps with prior authorization appeals or insurance denials.[1][2][9] - **Other Programs**: Check state Medicaid, compassionate use, or clinical trials. For commercial denials, use evidence-based appeals (e.g., genetic confirmation, age).[9] - **Financial Aid**: Explore non-profits like Cure SMA or general patient foundations. - **Reapply**: If circumstances change (e.g., income, insurance), resubmit.[3] ## Disclaimer This guide is for informational purposes only and based on publicly available data as of 2026. Eligibility, terms, and benefits can change; Novartis reserves the right to amend/discontinue programs.[4] Always consult your healthcare provider and contact Novartis directly at (855) 441-4363 or www.zolgensma-enrollment.com for personalized advice. Not a substitute for medical or legal counsel. Word count: 1028.

Program information last verified: March 30, 2026